Cancer Medicine (Feb 2023)

Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma

  • Yuanyuan Ren,
  • Ye Wang,
  • Lijiao Fang,
  • Mengchu Ma,
  • Lin Ge,
  • Chao Su,
  • Lingbiao Xin,
  • Jinyan He,
  • Jie Yang,
  • Xin Liu

DOI
https://doi.org/10.1002/cam4.5251
Journal volume & issue
Vol. 12, no. 4
pp. 4568 – 4578

Abstract

Read online

Abstract Background PRDM5 is considered a tumor suppressor in several types of solid tumors and is involved in multiple cellular processes. However, target genes regulated by PRDM5 in lung cancer and its potential mechanism are poorly defined. Methods Survival analysis was conducted using Kaplan‐Meier estimates based on the online databases. RNA‐sequencing and bioinformatics analysis were performed to identify the differentially expressed genes in PRDM5‐overexpressed A549 cells. Results We observed deregulated PRDM5 in several lung adenocarcinoma cell lines and its association with a poor prognosis. PRDM5 overexpression inhibited the proliferation of lung adenocarcinoma cells in vitro and suppressed tumor growth in a xenograft model. PRDM5 upregulated the promoter activity of SOCS1, which then inhibited the phosphorylation of JAK2 and STAT3. Conclusions Our study suggests that the low expression of PRDM5 promotes the proliferation of lung adenocarcinoma cells by downregulating SOCS1 and then upregulating the JAK2/STAT3 signaling pathway.

Keywords